<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199624</url>
  </required_header>
  <id_info>
    <org_study_id>1911069261</org_study_id>
    <nct_id>NCT04199624</nct_id>
  </id_info>
  <brief_title>Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets</brief_title>
  <official_title>Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hala Fadda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Butler University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in
      individuals with omeprazole induced hypochlorhydia. All participants will receive ascorbic
      acid tablets to measure the change in gastric pH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevation of gastric pH in patients with hypochlorhydria can reduce the solubility of weakly
      basic drugs. This may lead to poor and unpredictable systemic exposure for poorly soluble
      drugs. For example, extent of absorption of the kinase inhibitors, dasatinib (Sprycel) and
      erlotinib (Tarceva), is reduced by up to 61% and 46% respectively in patients on
      acid-reducing agents (ARAs). This pilot study is to evaluate the use of ascorbic acid,
      vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced
      hypochlorhdyria. Using pH/impedance testing, we are seeking to determine the magnitude and
      duration of pH change upon administration of 1000 mg of ascorbic acid in healthy subjects
      with proton-pump inhibitor induced hypochlorhydria. The results from this study will be used
      to evaluate the use of ascorbic acid as a drug-drug interaction mitigation strategy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gastric pH and duration of gastric pH \status</measure>
    <time_frame>Five hours</time_frame>
    <description>Gastric pH measurements will be continuously monitored throughout the study using a catheter-based pH monitoring system. Gastric pH versus time data will be collected for five hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypochlorhydria</condition>
  <arm_group>
    <arm_group_label>Experimental: omeprazole and ascorbic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole 20mg</intervention_name>
    <description>Omeprazole twice daily x 5 days</description>
    <arm_group_label>Experimental: omeprazole and ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Ascorbic acid x 1 on day 5</description>
    <arm_group_label>Experimental: omeprazole and ascorbic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, young males age 18-30 years with no prior history of gastrointestinal disease
             or symptoms.

        Exclusion Criteria:

          -  Hypochlorhydria (baseline use antacids, antisecretory medications, or surface agents
             including proton-pump inhibitors, H2 blockers, or sucralfate).

          -  Current or previous history of gastrointestinal disease including gastroesophageal
             reflux disease, Barrett's esophagus, peptic ulcer disease, dyspepsia, gastroparesis,
             bacterial overgrowth, microscopic colitis, gastric intestinal metaplasia or
             metaplastic atrophic gastritis, gastric neuroendocrine tumors, helicobacter pylori
             infection, inflammatory bowel disease (Crohn's disease or ulcerative colitis), celiac
             disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled
             thyroid disease, history of liver disease).

          -  History of gastric bypass or other abdominal surgeries excluding cholecystectomy or
             appendectomy &gt; 6 months prior to study initiation.

          -  Radiation therapy to the abdomen.

          -  Pregnant females.

          -  Ingestion of any prescription, over-the-counter, or herbal medications which may
             affect study interpretation.

          -  Currently a smoker

          -  Antibiotic use within the last 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikolina Roksandic, MD</last_name>
    <phone>317-654-3040</phone>
    <email>nikroksa@iu.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Andrea Shin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achlorhydria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

